- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
Why Are Drug Companies Funding Less Academic Research?
4 November 2009 1:46 pm
Fewer academic biomedical scientists are relying on industry support for their research than in the mid-'90s, according to a study highlighted today in The Boston Globe. That's the most surprising result of the latest survey of industry relationships at universities led by conflicts of interest expert Eric Campbell of the Massachusetts General Hospital. Campbell and his co-workers found that 20% of the more than 2000 life sciences faculty who responded in 2007 have direct industry funding, according to a paper in Health Affairs. That's down from 28% in a 1995 survey.
In a press release, the authors point to the growth of the National Institutes of Health budget and level research funding in industry as possible factors—as well as a growing public uproar about drug company payments. “Industry relationships may be declining because of increased regulation by universities as well as a general attitude among the public that working with industry is somehow bad,” Campbell says.
One of Campbell's longstanding messages hasn't changed: Industry relationships are pervasive in academic biomedicine.
More than half (53%) of respondents reported industry ties (such as consulting, speaking, or receiving research grants from drug companies), and they tended to be the more senior and productive faculty. Still, Campbell argues that it should be possible to find experts without industry connections to fill the rosters of federal advisory committees.
In a related story, The New York Times reviews provisions in the big health care reform bills that would require drug companies to report their payments to physicians (but not necessarily basic researchers) in a public database. Campbell served on an Institute of Medicine panel that earlier this year endorsed such a database for all payments as well as full disclosure of faculty members’ industry ties to their universities.